Purtier Placenta Live stem Cell Therapy Miracle - Mr Wilson Grandma is healthy now after 8 months
This video is from YouTube Channel-wilsonho ho. In his YouTube Wilson never mentions much. Just a short message, My grandmother is healthy now after 8months ...

By: Purtier Placenta Singapore Original

Read the rest here:
Purtier Placenta Live stem Cell Therapy Miracle - Mr Wilson Grandma is healthy now after 8 months - Video

Stem Cell Therapy Treatment for Spinal Cord Injury c6 c7 by Dr Alok Sharma, Mumbai, India
Improvement seen after Stem Cell Therapy Treatment for Spinal Cord Injury c6-c7 by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Standing toleran...

By: Neurogen Brain and Spine Institute

Read more:
Stem Cell Therapy Treatment for Spinal Cord Injury c6 c7 by Dr Alok Sharma, Mumbai, India - Video

MANILA, PhilippinesStem cell therapy should only apply to skin grafting for burn patients and not for anti-aging purposes, according to the Food and Drug Administration (FDA).

Up to now, there is no evidence that stem cell therapy has anti-aging effects, said FDA acting Director General Kenneth Hartigan-Go.

The FDA recognizes only hematopoietic (pertaining to the formation and development of blood cells) stem cell transplantation, corneal resurfacing with limbal stem cells and skin regeneration with epidermal stem cells as generally accepted standards of health care.

Asked if this meant anti-aging stem cell therapies would not be allowed in the Philippines, Go said: It means that if the health claim is for burn patients, requirements that need to be submittedlike clinical trial reportsare expected to be complete, whereas if the claim is for anti-aging, then the requirements may be more extensive and intensive considering that products for anti-aging claims are still controversial.

Facility accreditation

The FDA said it had been continuously collaborating with the Department of Healths Bureau of Health Facilities and Services (BHFS) in accrediting facilities that deal with human cells, tissues, and cellular and tissue-based products (HCT/Ps), laboratory and therapeutic activities or services.

As of Sept. 24, 51 facilities have applied for accreditation, and 11 of these have been inspected by the BHFS, the FDA said.

No automatic approval

Submission of an application, however, does not necessarily result in automatic approval.

The FDA guidelines require that all stem cell and cellular-based treatments offered in the country should first pass the agencys standards for safety, efficacy and quality.

Original post:
Stem cell therapy for burns, not aging, says FDA

Southern California Dermatologist Dr. Tess Mauricio: Regenerative Stem Cell Therapy w/Patient Marie
America #39;s Favorite Dermatologist, Dr. Tess Mauricio, talks Regenerative Stem Cell Therapy with her patient Marie, who is over 50 and now running Marathons! D...

By: awPVT

Go here to read the rest:
Southern California Dermatologist Dr. Tess Mauricio: Regenerative Stem Cell Therapy w/Patient Marie - Video

Rockville, Maryland (PRWEB) September 05, 2013

Fisher BioServices Inc., a leading provider of biorepository/biobanking and ultra cold chain logistics services, announced that Dan ODonnell, Associate Director of Cell Therapy Logistics, will speak at three upcoming industry conferences. Mr. ODonnell, who is widely known for his expertise on ultra cold chain distribution and regulatory compliance in transporting biologics and cryogenically frozen cell-based therapeutics, has been invited to present at the International Society for Cellular Therapy (ISCT) North America Regional Meeting in Philadelphia, Pennsylvania (September 811), the Stem Cell & Regenerative Medicine USA Congress in Cambridge, Massachusetts (September 30October 1), and the ColdChainIQ 11th Annual GDP & Temperature Management Logistics Global Forum in Chicago, Illinois (September 30October 4).

Mr. ODonnell will share his expertise on the challenges of moving high value biologics at ultra cold temperatures from the manufacturer to the patient bedsidein clinical trials as well as in the commercial marketplace. This will include an overview of how product packaging and clinical trial design can complicate logistics, add expense, and limit the number of clinical sites available for conducting phase II and phase III clinical trials. He will use a case study format to illustrate the technical challenges of meeting FDA requirements while moving products around the world at cryogenic temperatures, and share his experience with both autologous and allogeneic cell-based therapies.

Industry professionals whod like to learn more about the latest end-to-end cell therapy solutions from Fisher BioServices can register for Mr. ODonnells webinar - Ultra Cold Chain & Logistical Challenges in Cell Therapy Clinical and Commercial Development on October 10th, 2013. As Fisher BioServices Associate Director of Cell Therapy Logistics, Mr. ODonnell has worked with numerous clients and assisted them in designing and implementing their ultra cold chain strategies which include packaging, qualified shipping systems, and patient delivery mechanisms that are cost-effective and align with patient safety needs and FDA requirements. He brings extensive experience and insight to the process of commercialization and distribution of biological therapeutics. Mr. ODonnells webinar will include his insights and address some of the topics in his recent eBook, Commercially Successful Cell Therapies: Navigating the Ultra Cold Chain Distribution Minefield. Attendees will have the opportunity to ask questions. Mr. ODonnells eBook is available at blog.fisherbioservices.com. To learn more or register for the webinar, go to http://connect.fisherbioservices.com/webinar/cell_therapy_webinar_clinical_trials_commercialization

About Fisher BioServices

Fisher BioServices has 28 years of experience in biorepository/biobanking services, cold chain logistics, and related support services for health-related research. The company manages high value biological specimens, cell-based therapeutics, vaccines, tissues, and related data in support of both clinical and public health research; they store and distribute more than 170,000,000 samples in more than 20 facilities worldwide for government, academic, and pharmaceutical clients. Fisher BioServices is part of Thermo Fisher Scientific Inc., the world leader in serving science.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $13 billion, we have 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit http://www.thermofisher.com.

Read this article:
Fisher BioServices Intensifies Commitment for Cell Therapy Companies in Clinical Trials and Approaching ...

MS Video (before stem cell therapy)
Raising money to get to Panama.

By: jo80hanna

View original post here:
MS Video (before stem cell therapy) - Video

Short video on Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy
Improvement seen in just 3 months after Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy...

By: Neurogen Brain and Spine Institute

Follow this link:
Short video on Stem Cell Therapy Treatment for Duchenne Muscular Dystrophy - Video

Short video of Stem Cell Therapy Treatment for Muscular Dystrophy by Dr Alok Sharma Mumbai India
Improvement seen in just 6 months after Stem Cell Therapy Treatment for Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Earli...

By: Neurogen Brain and Spine Institute

Read more:
Short video of Stem Cell Therapy Treatment for Muscular Dystrophy by Dr Alok Sharma Mumbai India - Video

Short video on Stem Cell Therapy Treatment for Dopamine Responsive Dystonia by Dr Alok Sharma Mumbai
Improvement seen after Stem Cell Therapy Treatment for Dopamine Responsive Dystonia by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. His neck and...

By: Neurogen Brain and Spine Institute

Read more:
Short video on Stem Cell Therapy Treatment for Dopamine Responsive Dystonia by Dr Alok Sharma Mumbai - Video

By Philip C. Tubeza Philippine Daily Inquirer

MANILA, PhilippinesSaying that doctors were exacting exorbitant fees for what is still experimental medicine, the Philippine College of Physicians (PCP) launched Tuesday an online petition urging the Department of Health (DOH) to put a stop to experimental stem cell therapies in the country.

Human stem cell therapy for unproven indications is proliferating in the Philippines and posing serious safety issues to unknowing Filipinos The Philippine College of Physicians is alarmed by the false claims, misinformation and exorbitant fees for such stem cell treatments, read the petition on http://www.change.org.

The PCP urged the DOH to issue a cease and desist order to all doctors performing such therapies as the Philippine Health Insurance Corp. (PhilHealth) clarified that stem cell therapy was not covered by the governments universal healthcare program.

Cease and desist

We, the undersigned, call on the (DOH) to issue a cease and desist order to all doctors, clinics and hospitals that [offer] human stem cell therapy for unproven indications until scientific evidence to support claims of efficacy and safety are approved by the Food and Drug Administration, it said.

The PCP, the umbrella organization of Internal Medicine specialists in the country, said that transplanting human blood-forming stem cells to treat cancerous and noncancerous diseases of the blood was the most widely accepted clinical application of stem cell therapy.

The effectiveness and safety of human stem cell therapy has yet to be proven for heart, neurologic, skin, rheumatologic and gastrointestinal diseases, diabetes, hypertension, autism, cancer, aging and aesthetics, HIV/AIDS and other conditions, the group said.

Lack of evidence

Despite the lack of solid scientific evidence to support the [application] of human stem cell therapy for these conditions, reports of its use precisely for these conditions being received and exorbitant fees being paid by prominent personalities abound in media, the PCP said.

The rest is here:
Docs seek stop to expensive, experimental stem cell therapy

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will give the keynote address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine conference on Monday, August 19, 2013, at 12:15 p.m. EDT in Cleveland, Ohio. Dr. West will discuss the potential use of embryonic mesenchymal progenitor cells, generated using BioTimes PureStemtechnology, in regenerative medicine and will contrast the properties of those cells with adult-derived mesenchymal stem cells. He will also discuss how those cells can be utilized in the search for genes potentially useful in induced tissue regeneration (iTR). The presentation will be available on BioTimes website at http://www.biotimeinc.com/scientific-presentations.

MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine, August 19-21, 2013, is being held at the Cleveland Marriott Downtown at Key Center and is presented by Case Western Reserve University and the National Center for Regenerative Medicine.

About BioTime, Inc

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:

Additional information about BioTime can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

Read the original post:
BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine ...

My Stem Cell Therapy Fundraiser
Explain how I was able to raise funds toward my Stem Cell Therapy to treat Multiple Sclerosis...

By: Tiffany Talks Multiple Sclerosis

Read this article:
My Stem Cell Therapy Fundraiser - Video

Manila, Philippines -- Hospitals and health facilities offering stem cell therapy have until August 31 to apply for accreditation from the Department of Health (DoH).

DoH Secretary Enrique T. Ona said a number of hospitals in Metro Manila have already applied for accreditation to perform this "innovative" treatment that has not yet been accepted as standard mode of care in the country since it needs further tests and several more layers of research.

In the first mid-year convention of the Philippine Society for Stem Cell Medicine at the Manila Hotel yesterday, Ona reiterated that stem cell therapy is "the future of medicine."

"Stem cell therapy is not a cure-all medical treatment. Patients have yet to be presented first with standard of treatment, and in many cases, stem cell treatments have to be done in conjunction with other standard modalities of treatment," he said.

The Bureau of Health Facilities and Services (BHFS) of the DoH is accepting the applications for accreditation while a bio-ethics committee and a hospital-based review board will go over the applications and decide on their approval.

Five big hospitals in Metro Manila have already applied for accreditation, said Nick Lutero, chief of the BHFS.

Lutero said initial checks have revealed that these hospitals possess the required equipment needed for the treatment but they would still have to check on requirements set by the Food and Drug Administration (FDA) in relation to the practice.

Lutero said institutions that are offering stem cell treatments can still perform the procedures pending the approval of applications. However, once formal accreditations are already given, unaccredited institutions should cease offering stem cell therapy.

More here:
DOH sets deadline for stem cell therapy accreditation

Hello Doctor Zee 24 Taas Dr Nandini Gokulchandran talks about Stem Cell Therapy Treatments
Hello Doctor Zee 24 Taas Dr Nandini Gokulchandran talks about Stem Cell Therapy Treatments. Telecast on 23/6/2013 Stem Cell Therapy done at Dr Alok Sharma Ne...

By: Neurogen Brain and Spine Institute

Excerpt from:
Hello Doctor Zee 24 Taas Dr Nandini Gokulchandran talks about Stem Cell Therapy Treatments - Video

Stem Cell Therapy for Knees

By: Stem Cell U.S.

Read more:
Stem Cell Therapy for Knees - Video

Discussing: My intro Stem Cell Therapy
This video explains my intro into the World of MS.

By: Tiffany Vinson

See the rest here:
Discussing: My intro Stem Cell Therapy - Video

TAMPA, Fla., July 9, 2013 /PRNewswire/ -- Stem Cell Therapy for knee joint pain has been involved in multiple clinical trials worldwide. In the United States trials for knee arthritis and back pain with degenerative disc disease have undergone safety trials and phase studies for effectiveness. The safety profile for stem cell therapy in joints has been proven. Adverse effects are not seen as related to the stem cells. These studies were conducted with allogenic (other people's) stem cells. Naturally, if using your own stem cells, the issues which may be raised from someone else's stem cells is not a concern, and are therefore even safer. There are no immune rejection issues or communicable diseases that can be obtained by using your own cells.

Stem Cell Therapy for joints also do not carry surgical risks such as anesthesia, there is no greater risk for other postoperative complications such as blood clots, infections, or need for revision surgery if it is unsuccessful. Dr. Dennis Lox, a Regenerative and Sports Medicine physician in the Tampa Bay, Florida area (www.drlox.com), comments, "Surgery for joint replacement does carry some significant risks, as this is a highly invasive surgery. Knee and other joint replacement surgery consent forms do include the complication of death. More common problems are infection and blood clots. Stem Cell Therapy injections for joints are no more difficult than injecting cortisone into the knee," states Dr. Lox."There is preparation involved to get to that point, however the injection can be a simple, same-day, office-based procedure."

Dr. Lox notes, "Stem Cell Therapy for joint repair has been used for acute and chronic injuries, knee meniscal tears, loss of knee joint cartilage, and to stop the progression of degenerative arthritis. Even avascular necrosis (AVN) or osteonecrosis has been treated with Stem Cell Therapy. The secondary arthritis from joint collapse in avascular necrosis (AVN) can be significant leading to knee joint replacement. The useof stem cells is becoming a more common alternative to joint replacement."

Dr. Lox further notes, "Some patients may have already had one knee joint replaced with a bad outcome, and wish to avoid a second knee replacement. Others may not be healthy enough. Some medical disorders such as bad hear ailments may preclude having a knee replacement. In these cases, having a regenerative medicine procedure is an attractive, conservative option. Patients who are not medically suited for joint or knee replacement are generally good candidates for Stem Cell Therapy. The pursuit of conservative options in patients who wish to avoid surgery for joint disorders, may find Stem Cell Therapy as an attractive alternative."

About Dr. Dennis Lox Dr. Lox practices in the Tampa Bay Florida area. Dr. Lox is a Sports and Regenerative Medicine Physician, who specializes in the use of regenerative and restorative medicine to assist in treating athletic and arthritis conditions. Dr. Lox may be reached at (727) 462-5582 or visit Drlox.com.

http://www.drlox.com

Read more:
Stem Cell Therapy for Knee Pain: Safer than Surgery

#39;Bebot #39; Villar: Stem cell therapy made me weaker
MANILA, Philippines - A government official on Thursday said he is no believer in stem cell therapy after undergoing the procedure but getting zero health be...

By: TheABSCBNNews

Go here to see the original:
'Bebot' Villar: Stem cell therapy made me weaker - Video

Manila, Philippines --- Several congressmen have indeed undergone stem cell therapy in Germany and two of them died while serving the 15th Congress.

This was gathered from several sources as one outgoing congressman disclosed that a group of Mindanao mayors are set to depart for Europe to visit stem cell clinics in Germany.

''But virility and aesthetic enhancements are the reasons for the trip,'' said outgoing Agham Party-list Rep. Angelo Palmones in an interview yesterday.

Palmones admitted that one of the veteran solons who died during the 15th Congress was a stem cell therapy patient but whether or not the procedure contributed to his death remains unknown.

''He died of heart attack but the purpose of his stem cell treatment was to improve virility,'' said Palmones, outgoing vice chairman of the House Committee on Science and Technology.

Two others reportedly flew to Europe to seek treatment for cancer but both died.

A former broadcaster, Palmones authored House Resolution No. 1075 calling for a congressional investigation in aid of legislation on the operation of stem cell therapy clinics in malls in a bid to ensure the ''safety and security of patients.''

In a press statement the other day, the Philippine Medical Association (PMA) aired suspicions that ''three politicians'' from Mindanao may have died due to stem cell treatments from unauthorized practitioners.

Read the original post:
Was Stem Cell therapy behind death of 3 Solons?

ASCI Two Worlds of Stem Cell Therapy Animation
Asian Stem Cell Institute (ASCI) Two Worlds of Stem Cell Therapy Animation Autologous Stem cell Treatments, mobilized peripheral blood, bone marrow and adipo...

By: stemcellregeneration

Original post:
ASCI Two Worlds of Stem Cell Therapy Animation - Video